Kenneth R. Carson, MD
Articles
April 2nd 2024
Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib
Jason B. Gibbons, PhD Charles L. Bennett, MD, PhD, MPP Kenneth R. Carson, MD Gerard F. Anderson, PhD
Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
January 19th 2012
Economic Evaluation of Plerixafor for Stem Cell Mobilization
Steven M. Kymes, PhD Iskra Pusic, MD Dennis L. Lambert, PhD Martin Gregory, BA Kenneth R. Carson, MD John F. DiPersio, MD, PhD
Use of granulocyte colony-stimulating factor plus plerixafor for stem cell mobilization is cost-effective in pretreated patients with non-Hodgkin lymphoma.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 1st 2024 | Updated: November 21st 2024
Table Multiple Myeloma Trials November 2024
